Northside Capital Management LLC Purchases 5,280 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Northside Capital Management LLC increased its holdings in Thermo Fisher Scientific Inc. by 1,015.4%, acquiring an additional 5,280 shares, bringing their total to 5,800 shares worth $2.35 million.
• Major hedge funds, including Vanguard Group and UBS AM, have also boosted their stakes in Thermo Fisher, indicating a strong institutional interest, with hedge funds owning 89.23% of the stock.
• Recent analyst activity has predominantly favored the stock, with 16 analysts rating it as a Buy, and price targets ranging from $480 to $588.35, reflecting positive sentiment in the market.

Northside Capital Management LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1,015.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,800 shares of the medical research company's stock after buying an additional 5,280 shares during the period. Northside Capital Management LLC's holdings in Thermo Fisher Scientific were worth $2,352,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after purchasing an additional 230,382 shares during the period. Amundi raised its position in Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock valued at $1,426,316,000 after purchasing an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. raised its position in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after purchasing an additional 115,463 shares during the period. Pictet Asset Management Holding SA raised its position in Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after purchasing an additional 193,378 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after purchasing an additional 329,974 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TMO shares. Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $490.00 to $550.00 in a report on Thursday, September 11th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Evercore ISI reduced their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Finally, Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $469.41 on Wednesday. The business has a fifty day moving average of $474.01 and a 200 day moving average of $448.70. The firm has a market capitalization of $177.25 billion, a price-to-earnings ratio of 27.15, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.